CRVSCorvus Pharmaceuticals, Inc.Signing up patients
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified · Angioimmunoblastic T-cell Lymphoma · Follicular T-Cell Lymphoma · Nodal Peripheral T-Cell Lymphoma With TFH Phenotype · Systemic Anaplastic Large Cell Lymphoma · Lymphoma, T-Cell, Peripheral · Lymphoma, T-Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 150 (planned)
- Started
- Oct 2, 2024
- Main results expected
- Nov 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival
Measured over: Up to 4 years post study treatment initiation
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06561048 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC